20-F: COSCIENS Biopharma Inc. Navigates Strategic Shift Amidst Financial Reporting Weaknesses

COSCIENS Biopharma Inc. reports its annual results, highlighting a strategic shift towards natural-based products while addressing material weaknesses in internal financial controls.

Summary

• COSCIENS Biopharma Inc. reports its financial results for the year ended December 31, 2024, showcasing a strategic realignment towards natural-based products.
• The company completed a merger with Aeterna Zentaris Inc. on June 3, 2024, and subsequently changed its name.
• A Phase 3 trial for macimorelin in childhood growth hormone deficiency failed to meet its primary endpoints, leading to a strategic decision to discontinue investment in this area.
• The company is now focusing on its avenanthramide products and developing new oat-based nutraceuticals.
• Revenue increased to $9.6 million in 2024 from $7.1 million in 2023, primarily due to increased sales of oat-based products and macimorelin.
• The company reported a net loss of $15.3 million in 2024, compared to a net loss of $3.5 million in 2023.
• Material weaknesses in internal control over financial reporting were identified, prompting a remediation plan.
• The company acknowledges substantial doubt about its ability to continue as a going concern.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While revenue increased, the net loss significantly widened, and material weaknesses in internal controls were identified. The acknowledgment of substantial doubt about the company's ability to continue as a going concern further dampens the sentiment.

Positives

• Revenue increased to $9.6 million in 2024 from $7.1 million in 2023, driven by oat-based products and macimorelin sales.
• The company is actively developing oat-based pipeline products to address unmet needs within the nutraceuticals markets.
• A Phase 1-2a study evaluating avenanthramides for inflammation-based diseases is progressing, with the Phase 2a portion set to begin.
• The company has extended its supply and distribution agreement with Symrise AG for two years to December 31, 2026.

Negatives

• The company reported a net loss of $15.3 million in 2024, compared to a net loss of $3.5 million in 2023.
• A Phase 3 trial for macimorelin in childhood growth hormone deficiency failed to meet its primary endpoints.
• Material weaknesses in internal control over financial reporting were identified.
• The company acknowledges substantial doubt about its ability to continue as a going concern.

Risks

• The company acknowledges substantial doubt about its ability to continue as a going concern.
• Material weaknesses in internal control over financial reporting were identified, potentially affecting the accuracy and timeliness of financial reporting.
• The failure of the DETECT-trial may impact the market for macimorelin in adult hormone growth deficiency.
• The company relies on one distribution partner for a large portion of its revenues, creating economic dependence.
• The transition to a new presidential administration in the United States, including the potential use and effects of tariffs, could materially impact costs and revenues.

Future Outlook

The company plans to finance future operations and capital expenditures primarily through product sales and cash on hand. The company is exploring and validating strategic alternatives for macimorelin, including, but not limited to, potential divestment of the asset.

Industry Context

The cosmeceutical, nutraceutical and biopharmaceutical fields are highly competitive. New products developed by other companies in the industry could make our current and future products uncompetitive or significantly less competitive.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• A comprehensive analysis would require specific benchmarks related to revenue growth, R&D spending, and profitability metrics of comparable companies in the cosmeceutical, nutraceutical, and biopharmaceutical sectors.
• Without specific data on competitors like Symrise AG, Novo Nordisk, or other companies in the active ingredient and pharmaceutical markets, a detailed comparison is not possible.

Related Party Transactions

• During the year ended December 31, 2024, the Company made payments for research and development expenditures to Angiogenesis Foundation for which a Director of the Company is the CEO of the Foundation of $50 (2023 $201 and 2022 $105).

Stakeholder Impact

• Shareholders face increased risk due to the company's financial instability and material weaknesses in internal controls.
• Employees may experience uncertainty due to potential restructuring and cost-cutting measures.
• Customers may be affected by changes in product focus and potential disruptions in supply.
• Suppliers may face increased scrutiny and potential changes in purchasing patterns.
• Creditors face increased risk due to the company's going concern uncertainty.

Next Steps

• The company is implementing a remediation plan to address the material weaknesses in internal control over financial reporting.
• The company is exploring and validating strategic alternatives for macimorelin, including, but not limited to, potential divestment of the asset.
• The company plans to bring its oat beta glucan chewable product to the wellness and functional food market B2C via various e-commerce platforms during the first 6 months of 2025.
• The company is initiating the production of enriched oat flour at small commercial scale at the Edmonton facility.
• The company is working towards the completion of the PGX100L at the Natex Termitz facility, expected by Q2, 2025.

Key Dates

Keywords

COSCIENS Biopharma, macimorelin, avenanthramides, oat beta glucan, financial results, internal control, going concern, biopharmaceutical, nutraceutical, cosmeceutical